Medlab Clinical (ASX:MDC) has entered into a collaborative agreement with Chronic Pain Australia regarding consumer and health practitioner medicinal cannabis education throughout Australia.
The company said the project aims to provide professional education services to people living with chronic pain and their relevant healthcare providers about medicinal cannabis.
Chronic Pain Australia is a not-for-profit consumer organisation dedicated to reducing health and social barriers faced by people living with chronic pain. It supports over 35,000 people living with chronic pain each month.
Chronic Pain Australia has partnered with the Australian Pain Society and Faculty of Pain Medicine to develop Australia's first National Pain Strategy.
“We openly welcome this alliance with Chronic Pain Australia, we understand that pain management has to extend beyond opioids, their derivatives, and lifestyle management; new therapies such as NanaBis equate to more options, and together we can work on better patient outcomes,” said MDC CEO Dr Sean Hall.
"NanaBis is currently in clinical trial at Royal North Shore Hospital, and available under the Australian Government’s Special Access Scheme (SAS). Current data provided from both mechanisms is very positive and extremely encouraging."